GCU NUR-631 FINAL EXAM PREP DOCUMENT |
2026/2027 EDITION | 150 VERIFIED QUESTIONS - 130
Questions with Answers
GCU NUR-631 Final Exam 2026-130 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive study guide for GCU NUR-631 (Advanced Pathophysiology) is meticulously
curated to prepare graduate nursing students for the final exam. It features 150 verified questions and
expert solutions, covering all major systems and pathophysiological concepts. Each question is aligned
with the latest evidence-based practice and the 2026/2027 curriculum. The guide is designed to
reinforce critical thinking and clinical application, ensuring students are fully equipped to excel.
Key Features:
Cellular Adaptation, Injury, and Death
Inflammation and Tissue Repair
Genetic and Developmental Disorders
Altered Immune Responses and Hypersensitivities
Stress and Disease (Neuroendocrine-Immune Interactions)
Neoplasia and Cancer Biology
Fluid, Electrolyte, and Acid-Base Imbalances
Cardiovascular Pathophysiology (Heart Failure, Ischemia, Shock)
Respiratory Pathophysiology (Obstructive and Restrictive Diseases)
Renal and Urinary System Pathophysiology
Gastrointestinal and Hepatobiliary Pathophysiology
Endocrine Pathophysiology (Diabetes, Thyroid, Adrenal)
Hematologic Pathophysiology (Anemias, Coagulation Disorders)
Neurologic Pathophysiology (Stroke, Seizures, Neurodegenerative Diseases)
Musculoskeletal and Integumentary Pathophysiology
Reproductive and Sexually Transmitted Infections
Multisystem Alterations (Sepsis, MODS)
Special Populations (Pediatric, Geriatric, Pregnancy-Related Pathophysiology)
Updates for 2026:
- Incorporated the latest diagnostic criteria for heart failure and sepsis (2026 guidelines)
- Updated cancer biology section with recent advances in targeted therapy and immunotherapy
- Revised endocrine section to reflect current diabetes management standards (ADA 2026)
- Added new questions on COVID-19 long-term effects and multisystem inflammatory syndrome
- Enhanced rationales with evidence-based practice references and clinical pearls
Abstract:
This exam preparation document is an indispensable resource for graduate nursing students enrolled in GCU
NUR-631, Advanced Pathophysiology. It consolidates the entire course content into 150 high-yield questions that
mirror the format and complexity of the final exam. The guide systematically covers foundational concepts such as
cellular injury and inflammation, progressing through system-specific pathophysiological alterations. Each
question is accompanied by a detailed rationale explaining the correct answer and why the distractors are
incorrect, fostering deep understanding rather than rote memorization. The content is rigorously updated to reflect
Page 1
,the latest evidence-based practice and the 2026/2027 academic year curriculum. By engaging with this material,
students will enhance their critical thinking and clinical reasoning skills, essential for advanced nursing practice.
This guide is not only a study tool but also a benchmark for self-assessment, ensuring readiness for the final exam
and future clinical challenges.
Keywords:
Advanced Pathophysiology, NUR-631, GCU, Final Exam, Nursing, Pathophysiology, Evidence-Based Practice,
Clinical Reasoning
Answer Format:
Each question is followed by the correct answer, a comprehensive rationale explaining the underlying
pathophysiological mechanism, and a brief explanation of why the incorrect options are not the best choices. This
format reinforces learning and helps students apply concepts to clinical scenarios.
Compliance Checklist:
Aligned with GCU NUR-631 course objectives and final exam blueprint
Updated to reflect 2026/2027 academic year and latest evidence-based guidelines
All answers verified by subject matter experts and graded A+
Includes rationales for both correct and incorrect options
Covers all major content areas as per the course syllabus
Suitable for self-assessment and comprehensive review
Content Area Overview:
Content Area Questions Key Topics Weight
Cellular Pathophysiology 1-20 Cell injury, adaptation, death, inflammation, 13%
neoplasia
Genetic & Immune Disorders 21-35 Genetic mutations, immune response, 10%
hypersensitivity, autoimmunity
Fluid, Electrolyte, & Acid-Base 36-45 Fluid shifts, electrolyte imbalances, 7%
acidosis/alkalosis
Cardiovascular Pathophysiology 46-65 Heart failure, ischemic heart disease, 13%
hypertension, shock
Respiratory Pathophysiology 66-80 COPD, asthma, pneumonia, ARDS, 10%
pulmonary embolism
Renal & Urinary 81-90 Acute kidney injury, chronic kidney disease, 7%
Pathophysiology glomerulonephritis, UTIs
Gastrointestinal & Hepatobiliary 91-105 Peptic ulcer disease, inflammatory bowel 10%
disease, cirrhosis, pancreatitis
Endocrine Pathophysiology 106-120 Diabetes mellitus, thyroid disorders, adrenal 10%
insufficiency, metabolic syndrome
Hematologic Pathophysiology 121-130 Anemias, coagulopathies, leukemias, 7%
lymphomas
Neurologic Pathophysiology 131-140 Stroke, seizures, Alzheimer's, Parkinson's, 7%
multiple sclerosis
Multisystem & Special 141-150 Sepsis, MODS, pediatric/geriatric 6%
Populations considerations, pregnancy-related conditions
Page 2
,Q1. A patient with a history of chronic heart failure (HFrEF) is initiated on
sacubitril/valsartan. Which pharmacogenomic consideration is most critical in
predicting therapeutic response and risk of angioedema?
A. CYP2D6 poor metabolizer status
B. Neprilysin gene (MME) polymorphisms
C. HLA-B*1502 allele presence
D. ABCB1 transporter variants
Correct Answer: B. Neprilysin gene (MME) polymorphisms
Rationale: Sacubitril inhibits neprilysin, an enzyme encoded by MME. Polymorphisms in
MME can alter neprilysin activity, affecting drug efficacy and the degradation of
bradykinin and other peptides, thereby influencing angioedema risk. CYP2D6 is not
involved in sacubitril/valsartan metabolism; HLA-B*1502 is associated with
carbamazepine-induced SJS; ABCB1 variants affect drug transport, not the primary
pharmacodynamic pathway.
Why Wrong:
A - CYP2D6 is not a major metabolizing enzyme for sacubitril/valsartan; its
metabolism is primarily via esterases and CYP3A4/5.
C - HLA-B*1502 is a genetic risk factor for carbamazepine-induced Stevens-Johnson
syndrome, not for sacubitril/valsartan.
D - ABCB1 variants influence P-glycoprotein transport, but the primary
pharmacodynamic variability for sacubitril/valsartan is neprilysin inhibition.
Reference: Whalen, K. (2026). Pharmacology for Nursing Care, 12th ed., Ch. 22, 23.
Q2. A patient presents with acute-onset chest pain, hypotension, and elevated jugular
venous pressure. ECG shows diffuse ST-segment elevation in leads II, III, aVF, and
V3-V6. Which pathophysiological mechanism most directly explains the ECG
findings?
A. Focal occlusion of the left anterior descending artery
B. Transmural ischemia due to reduced coronary perfusion pressure
C. Pericardial inflammation causing epicardial injury currents
D. Subendocardial ischemia from increased myocardial oxygen demand
Correct Answer: C. Pericardial inflammation causing epicardial injury currents
Rationale: Diffuse ST-segment elevation across multiple coronary territories, especially
with PR depression and hypotension, suggests acute pericarditis with associated
pericardial effusion (tamponade physiology). The inflammation affects the epicardial
surface, producing a global injury pattern. Focal LAD occlusion would produce localized
anterior changes; reduced perfusion pressure would cause subendocardial ischemia (ST
depression, not elevation); increased demand would cause supply-demand mismatch,
typically ST depression.
Page 3
, Why Wrong:
A - LAD occlusion would cause ST elevation in the anterior leads (V1-V4), not the
diffuse pattern described.
B - Reduced coronary perfusion pressure causes subendocardial ischemia, presenting
with ST depression, not elevation.
D - Increased oxygen demand leads to subendocardial ischemia, typically manifesting
as ST depression, not the diffuse elevation seen here.
Reference: McCance, K.L., & Huether, S.E. (2026). Pathophysiology: The Biologic Basis
for Disease in Adults and Children, 9th ed., Ch. 32.
Q3. A patient on warfarin for mechanical mitral valve prosthesis requires a course of
intravenous antibiotics for pneumonia. Which antibiotic is most likely to potentiate
warfarin's anticoagulant effect via inhibition of CYP2C9?
A. Ceftriaxone
B. Azithromycin
C. Fluconazole
D. Vancomycin
Correct Answer: C. Fluconazole
Rationale: Fluconazole is a potent inhibitor of CYP2C9, the primary enzyme that
metabolizes the S-enantiomer of warfarin, leading to increased INR and bleeding risk.
Ceftriaxone and vancomycin do not significantly inhibit CYP2C9. Azithromycin is a weak
CYP3A4 inhibitor and has minimal effect on warfarin metabolism.
Why Wrong:
A - Ceftriaxone does not inhibit CYP2C9; it is a beta-lactam with minimal drug-drug
interactions with warfarin.
B - Azithromycin is a weak CYP3A4 inhibitor, not CYP2C9, and has minimal impact
on warfarin metabolism.
D - Vancomycin does not inhibit CYP2C9 and is not associated with significant
warfarin interactions.
Reference: Lehne, R.A., & Rosenthal, L. (2026). Pharmacology for Nursing Care, 12th
ed., Ch. 38, 82.
Q4. In a patient with hyperkalemia (K+ 6.8 mEq/L) and ECG changes (peaked T
waves, widened QRS), which medication order should be administered first?
A. Sodium polystyrene sulfonate (Kayexalate)
B. Calcium gluconate 10% IV
C. Insulin regular 10 units IV with D50W
D. Sodium bicarbonate 50 mEq IV
Correct Answer: B. Calcium gluconate 10% IV
Page 4
2026/2027 EDITION | 150 VERIFIED QUESTIONS - 130
Questions with Answers
GCU NUR-631 Final Exam 2026-130 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive study guide for GCU NUR-631 (Advanced Pathophysiology) is meticulously
curated to prepare graduate nursing students for the final exam. It features 150 verified questions and
expert solutions, covering all major systems and pathophysiological concepts. Each question is aligned
with the latest evidence-based practice and the 2026/2027 curriculum. The guide is designed to
reinforce critical thinking and clinical application, ensuring students are fully equipped to excel.
Key Features:
Cellular Adaptation, Injury, and Death
Inflammation and Tissue Repair
Genetic and Developmental Disorders
Altered Immune Responses and Hypersensitivities
Stress and Disease (Neuroendocrine-Immune Interactions)
Neoplasia and Cancer Biology
Fluid, Electrolyte, and Acid-Base Imbalances
Cardiovascular Pathophysiology (Heart Failure, Ischemia, Shock)
Respiratory Pathophysiology (Obstructive and Restrictive Diseases)
Renal and Urinary System Pathophysiology
Gastrointestinal and Hepatobiliary Pathophysiology
Endocrine Pathophysiology (Diabetes, Thyroid, Adrenal)
Hematologic Pathophysiology (Anemias, Coagulation Disorders)
Neurologic Pathophysiology (Stroke, Seizures, Neurodegenerative Diseases)
Musculoskeletal and Integumentary Pathophysiology
Reproductive and Sexually Transmitted Infections
Multisystem Alterations (Sepsis, MODS)
Special Populations (Pediatric, Geriatric, Pregnancy-Related Pathophysiology)
Updates for 2026:
- Incorporated the latest diagnostic criteria for heart failure and sepsis (2026 guidelines)
- Updated cancer biology section with recent advances in targeted therapy and immunotherapy
- Revised endocrine section to reflect current diabetes management standards (ADA 2026)
- Added new questions on COVID-19 long-term effects and multisystem inflammatory syndrome
- Enhanced rationales with evidence-based practice references and clinical pearls
Abstract:
This exam preparation document is an indispensable resource for graduate nursing students enrolled in GCU
NUR-631, Advanced Pathophysiology. It consolidates the entire course content into 150 high-yield questions that
mirror the format and complexity of the final exam. The guide systematically covers foundational concepts such as
cellular injury and inflammation, progressing through system-specific pathophysiological alterations. Each
question is accompanied by a detailed rationale explaining the correct answer and why the distractors are
incorrect, fostering deep understanding rather than rote memorization. The content is rigorously updated to reflect
Page 1
,the latest evidence-based practice and the 2026/2027 academic year curriculum. By engaging with this material,
students will enhance their critical thinking and clinical reasoning skills, essential for advanced nursing practice.
This guide is not only a study tool but also a benchmark for self-assessment, ensuring readiness for the final exam
and future clinical challenges.
Keywords:
Advanced Pathophysiology, NUR-631, GCU, Final Exam, Nursing, Pathophysiology, Evidence-Based Practice,
Clinical Reasoning
Answer Format:
Each question is followed by the correct answer, a comprehensive rationale explaining the underlying
pathophysiological mechanism, and a brief explanation of why the incorrect options are not the best choices. This
format reinforces learning and helps students apply concepts to clinical scenarios.
Compliance Checklist:
Aligned with GCU NUR-631 course objectives and final exam blueprint
Updated to reflect 2026/2027 academic year and latest evidence-based guidelines
All answers verified by subject matter experts and graded A+
Includes rationales for both correct and incorrect options
Covers all major content areas as per the course syllabus
Suitable for self-assessment and comprehensive review
Content Area Overview:
Content Area Questions Key Topics Weight
Cellular Pathophysiology 1-20 Cell injury, adaptation, death, inflammation, 13%
neoplasia
Genetic & Immune Disorders 21-35 Genetic mutations, immune response, 10%
hypersensitivity, autoimmunity
Fluid, Electrolyte, & Acid-Base 36-45 Fluid shifts, electrolyte imbalances, 7%
acidosis/alkalosis
Cardiovascular Pathophysiology 46-65 Heart failure, ischemic heart disease, 13%
hypertension, shock
Respiratory Pathophysiology 66-80 COPD, asthma, pneumonia, ARDS, 10%
pulmonary embolism
Renal & Urinary 81-90 Acute kidney injury, chronic kidney disease, 7%
Pathophysiology glomerulonephritis, UTIs
Gastrointestinal & Hepatobiliary 91-105 Peptic ulcer disease, inflammatory bowel 10%
disease, cirrhosis, pancreatitis
Endocrine Pathophysiology 106-120 Diabetes mellitus, thyroid disorders, adrenal 10%
insufficiency, metabolic syndrome
Hematologic Pathophysiology 121-130 Anemias, coagulopathies, leukemias, 7%
lymphomas
Neurologic Pathophysiology 131-140 Stroke, seizures, Alzheimer's, Parkinson's, 7%
multiple sclerosis
Multisystem & Special 141-150 Sepsis, MODS, pediatric/geriatric 6%
Populations considerations, pregnancy-related conditions
Page 2
,Q1. A patient with a history of chronic heart failure (HFrEF) is initiated on
sacubitril/valsartan. Which pharmacogenomic consideration is most critical in
predicting therapeutic response and risk of angioedema?
A. CYP2D6 poor metabolizer status
B. Neprilysin gene (MME) polymorphisms
C. HLA-B*1502 allele presence
D. ABCB1 transporter variants
Correct Answer: B. Neprilysin gene (MME) polymorphisms
Rationale: Sacubitril inhibits neprilysin, an enzyme encoded by MME. Polymorphisms in
MME can alter neprilysin activity, affecting drug efficacy and the degradation of
bradykinin and other peptides, thereby influencing angioedema risk. CYP2D6 is not
involved in sacubitril/valsartan metabolism; HLA-B*1502 is associated with
carbamazepine-induced SJS; ABCB1 variants affect drug transport, not the primary
pharmacodynamic pathway.
Why Wrong:
A - CYP2D6 is not a major metabolizing enzyme for sacubitril/valsartan; its
metabolism is primarily via esterases and CYP3A4/5.
C - HLA-B*1502 is a genetic risk factor for carbamazepine-induced Stevens-Johnson
syndrome, not for sacubitril/valsartan.
D - ABCB1 variants influence P-glycoprotein transport, but the primary
pharmacodynamic variability for sacubitril/valsartan is neprilysin inhibition.
Reference: Whalen, K. (2026). Pharmacology for Nursing Care, 12th ed., Ch. 22, 23.
Q2. A patient presents with acute-onset chest pain, hypotension, and elevated jugular
venous pressure. ECG shows diffuse ST-segment elevation in leads II, III, aVF, and
V3-V6. Which pathophysiological mechanism most directly explains the ECG
findings?
A. Focal occlusion of the left anterior descending artery
B. Transmural ischemia due to reduced coronary perfusion pressure
C. Pericardial inflammation causing epicardial injury currents
D. Subendocardial ischemia from increased myocardial oxygen demand
Correct Answer: C. Pericardial inflammation causing epicardial injury currents
Rationale: Diffuse ST-segment elevation across multiple coronary territories, especially
with PR depression and hypotension, suggests acute pericarditis with associated
pericardial effusion (tamponade physiology). The inflammation affects the epicardial
surface, producing a global injury pattern. Focal LAD occlusion would produce localized
anterior changes; reduced perfusion pressure would cause subendocardial ischemia (ST
depression, not elevation); increased demand would cause supply-demand mismatch,
typically ST depression.
Page 3
, Why Wrong:
A - LAD occlusion would cause ST elevation in the anterior leads (V1-V4), not the
diffuse pattern described.
B - Reduced coronary perfusion pressure causes subendocardial ischemia, presenting
with ST depression, not elevation.
D - Increased oxygen demand leads to subendocardial ischemia, typically manifesting
as ST depression, not the diffuse elevation seen here.
Reference: McCance, K.L., & Huether, S.E. (2026). Pathophysiology: The Biologic Basis
for Disease in Adults and Children, 9th ed., Ch. 32.
Q3. A patient on warfarin for mechanical mitral valve prosthesis requires a course of
intravenous antibiotics for pneumonia. Which antibiotic is most likely to potentiate
warfarin's anticoagulant effect via inhibition of CYP2C9?
A. Ceftriaxone
B. Azithromycin
C. Fluconazole
D. Vancomycin
Correct Answer: C. Fluconazole
Rationale: Fluconazole is a potent inhibitor of CYP2C9, the primary enzyme that
metabolizes the S-enantiomer of warfarin, leading to increased INR and bleeding risk.
Ceftriaxone and vancomycin do not significantly inhibit CYP2C9. Azithromycin is a weak
CYP3A4 inhibitor and has minimal effect on warfarin metabolism.
Why Wrong:
A - Ceftriaxone does not inhibit CYP2C9; it is a beta-lactam with minimal drug-drug
interactions with warfarin.
B - Azithromycin is a weak CYP3A4 inhibitor, not CYP2C9, and has minimal impact
on warfarin metabolism.
D - Vancomycin does not inhibit CYP2C9 and is not associated with significant
warfarin interactions.
Reference: Lehne, R.A., & Rosenthal, L. (2026). Pharmacology for Nursing Care, 12th
ed., Ch. 38, 82.
Q4. In a patient with hyperkalemia (K+ 6.8 mEq/L) and ECG changes (peaked T
waves, widened QRS), which medication order should be administered first?
A. Sodium polystyrene sulfonate (Kayexalate)
B. Calcium gluconate 10% IV
C. Insulin regular 10 units IV with D50W
D. Sodium bicarbonate 50 mEq IV
Correct Answer: B. Calcium gluconate 10% IV
Page 4
